Post anti-PD-1 melanoma

Clinical trials for Post anti-PD-1 melanoma explained in plain language.

Never miss a new study

Get alerted when new Post anti-PD-1 melanoma trials appear

Sign up with your email to follow new studies for Post anti-PD-1 melanoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New immune drug shows promise in early trial for Hard-to-Treat cancers

Disease control Ongoing

This study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …

Matched conditions: POST ANTI-PD-1 MELANOMA

Phase 1/2 • Sponsor: Ascendis Pharma Oncology Division A/S • Aim: Disease control

Last updated Sep 13, 2026 00:00 UTC

Post anti-PD-1 melanoma

Get alerted when new Post anti-PD-1 melanoma trials appear

New immune drug shows promise in early trial for Hard-to-Treat cancers